Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?
TheFly reported on June 11 that XERS announced that the USPTO issued a notice of allowance for U.S. Patent Application No.
Xeris Biopharma Holdings Inc. (XERS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 7,804,758 | $61,813,683 | +1% | 0.03% |
| 2. | Armistice Capital Steven Boyd | 1,958,702 | $15,512,920 | +3% | 0.19% |
| 3. | Parkman Healthcare Partners Greg Martinez | 1,807,621 | $14,316,358 | +6% | 1.47% |
| 4. | Algert Coldiron Investors Peter Algert And Kevin Coldiron | 1,742,942 | $13,804,101 | +51% | 0.16% |
| 5. | AQR Capital Management Cliff Asness | 1,540,985 | $12,204,601 | +11% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.38 | 25,000 | $109,475.00 | 1,708,585 | 2025-06-13 | Filing | |
| $2.25 | 4,515 | $10,147.01 | 25,200 | 2024-08-12 | Filing | |
| $2.37 | 4,285 | $10,134.03 | 20,685 | 2024-08-09 | Filing | |
| $1.91 | 5,400 | $10,314.00 | 16,400 | 2024-05-10 | Filing | |
| $2.16 | 4,500 | $9,720.00 | 11,000 | 2024-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.50 | 5,000 | $42,500.00 | 1,361,053 | 2026-08-12 | Filing | |
| $8.02 | 15,000 | $120,240.00 | 1,676,126 | 2026-08-03 | Filing | |
| $8.01 | 16,666 | $133,552.99 | 1,144,462 | 2026-08-03 | Filing | |
| $8.52 | 27,600 | $235,276.20 | 1,366,053 | 2026-07-07 | Filing | |
| $8.50 | 17,400 | $147,900.00 | 1,393,653 | 2026-07-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,525,539 | $115,042,270 | 0% | |
| 2. | 7,340,229 | $58,134,614 | 0% | |
| 3. | 4,821,566 | $38,186,803 | 0% | |
| 4. | 4,718,183 | $37,374,872 | 0% | |
| 5. | 4,385,141 | $34,730,316 | 0.01% |
News See All
12 Best Low-Priced Pharma Stocks to Buy Right Now
Investors looking for large returns without making a sizable initial commitment are still drawn to low-priced companies.
Jim Cramer Discussed 15 Stocks, Including Broadcom, Netflix, and His Skepticism Toward Tech Stocks
In this article, we will look at the stocks Jim Cramer commented on, as he explained that tech stocks cannot be trusted to lead anymore.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2026 Earnings Call Transcript
Allison Wey: Thank you, Sarah. Good morning, everyone, and welcome to Xeris' First Quarter Financial Results Conference Call.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript March 2, 2026Xeris Biopharma Holdings, Inc. beats earnings expectations.
Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory
We came across a bullish thesis on Xeris Biopharma Holdings, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research and Rudy Does Research.
7 Hidden Multibagger Stocks to Invest In
Multibaggers often take the limelight because of their stellar returns, but it isn’t always easy to catch these multibaggers while they are in the process of generating these returns.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2025 Earnings Call Transcript November 6, 2025Xeris Biopharma Holdings, Inc. misses on earnings expectations.
Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a Chicago-based commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases.
10 Best Biotech Stocks to Buy Under $10
The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC's "Squawk Box" on July 25 to discuss various topics, including the current status of the biotech industry and what to expect...